share_log

Wells Fargo Maintains Equal-Weight on Bluebird Bio, Lowers Price Target to $3

Benzinga ·  Mar 27 20:34

Wells Fargo analyst Yanan Zhu maintains bluebird bio (NASDAQ:BLUE) with a Equal-Weight and lowers the price target from $4 to $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment